DuPont settles pollution charges for $1.3m


Chemical titan DuPont has agreed a settlement with US authorities over eight hazardous chemical leaks from the company’s plant in Belle, US, between 2006 and 2010. DuPont will pay $1.3 million (£770,000) in fines, and make various improvements to its safety and emergency response procedures, which the firm estimates will cost a further $1.3 million to implement.

The allegations from the US Environmental Protection Agency (EPA) and Department of Justice contend that DuPont ‘released harmful quantities of hazardous substances and then did not report the releases to the National Response Center, State Emergency Response Commission and Local Emergency Planning Committee in a timely manner’. The most serious of these releases include 80 tons of methanol leaking into the Kanawha river, 900kg of methyl chloride gas, and a phosgene leak that killed a worker at the plant.

Since 2010, DuPont has been working under an EPA administrative order to correct problems that led to these releases, which it says has already cost $6.8 million.


Related Content

DuPont and Monsanto settle Roundup dispute

12 April 2013 Business

news image

Firms drop expensive ongoing litigation in favour of a licensing deal

Ansun settles fraud case for $2m

13 January 2015 Business

news image

Executives fiddled timesheets to overcharge US funding agency on grants and research contracts

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent